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ABSTRACT
Purpose: This study evaluated the usefulness of intraprocedural contrast-enhanced ultrasound (CEUS)/
ultrasound (US) fusion imaging using a perflubutane-based contrast agent combined with preproce-
dural auto sweep three-dimensional US to obtain volume data for guidance and evaluation of the
therapeutic efficacy of radiofrequency ablation (RFA).
Methods: This uncontrolled clinical trial included 50 hepatocellular carcinomas (HCCs) with a mean
diameter of 15.3mm that had been treated by RFA. The efficacy of RFA was evaluated by CEUS/US
fusion imaging during the procedure. If the ablation was deemed to be inadequate, further ablation
was performed until adequate ablation was achieved. Contrast-enhanced computed tomography
(CECT) or contrast-enhanced magnetic resonance imaging (CEMRI) was performed a month after RFA,
and the images obtained using each modality were reviewed to evaluate the efficacy of RFA.
Results: Thirty-three of the 50 lesions were evaluated by CEUS/US fusion imaging as having been
adequately ablated after the first RFA procedure. The ablation was evaluated as inadequate in the
remaining 17 lesions, for which additional ablation was performed. Ninety-eight (49/50) of all HCCs
were evaluated as having been eventually adequately ablated on intraprocedural CEUS/US fusion
imaging. The concordance rate for evaluations between intraprocedural CEUS/US fusion imaging and
CECT/CEMRI performed 1 month after RFA was 88% (44/50). The kappa value for agreement between
the two methods of evaluation was 0.792.
Conclusion: Intraprocedural fusion imaging combining CEUS and auto sweep three-dimensional US
appears to be a useful modality for RFA guidance and evaluation of therapeutic efficacy of RFA in
patients with HCC.
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Contrast-enhanced computed tomography (CECT) and con-
trast-enhanced magnetic resonance imaging (CEMRI) are the
most widely used imaging techniques for evaluation of the
therapeutic efficacy of radiofrequency ablation (RFA) for hep-
atocellular carcinoma (HCC) [1–4]. However, neither of these
imaging techniques can be performed during the RFA pro-
cedure to evaluate its therapeutic efficacy. The recent
European Federation of Societies for Ultrasound in Medicine
and Biology guidelines have highlighted the role of contrast-
enhanced ultrasound (CEUS) as a cost-effective technique
with a good safety profile, not only for characterization and
detection of focal liver lesions, but also for monitoring tumor
response after curative, locoregional or systemic treatment
for HCC [5–7]. However, the ablation margin can be hard to
determine by CEUS because of the difficulty in identifying
the edge between the ablated HCC and the ablated adjacent
liver parenchyma using this imaging modality alone [8,9].
In contrast, disappearance of the vascularity of HCC after
RFA can be evaluated by fusion imaging using a combin-
ation of CEUS and CECT [10]/CEMRI [11] because CEUS and
arterial-phase CECT or hepatobiliary-phase CEMRI, used as
reference, allows the location of the treated HCC to be
visualized [10,11]. In our studies, we have used global posi-
tioning system (GPS) marks, whereby small green cross
graphics appear simultaneously in CECT (arterial phase) [10]/
CEMRI (hepatobiliary phase) [11] and CEUS, enabling the
location of the ablated HCC to be confirmed and differenti-
ated from the adjacent ablated liver parenchyma. Fusion
imaging combining CEUS and arterial-phase CECT as
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reference appears to be a useful method for evaluating the
therapeutic efficacy of RFA for hypervascular HCCs detected
using conventional US [10]. Fusion imaging combining CEUS
and hepatobiliary-phase CEMRI also appears to be useful for
evaluating the therapeutic efficacy of RFA for HCCs identified
as having isoechoic or unclear margins by conventional US
[12]. The usefulness of fusion imaging combining CEUS and
CECT/CEMRI for evaluating the therapeutic efficacy of RFA
has been reported by several investigators [13,14]. The
reported concordance rate for the results of the RFA efficacy
evaluation between intraprocedural CEUS and CECT/CEMRI
fusion imaging and CECT/CEMRI performed within 30 days
after RFA was 91.1% (72/79) [13].
However, because of registration error, a fusion image
does not always precisely correspond to the US image. One of
the reasons for registration error is the difference in timing of
breath-holding during image acquisition by each modality. CT
images are usually obtained at the end of inspiration with a
breath-hold whereas magnetic resonance images are obtained
at the end of expiration after a breath-hold. US images are
acquired with patients holding their breath during gentle res-
piration, which is adequate for puncture of the lesion for RFA.
Therefore, the image registration error associated with use of
CEUS/CECT or CEMRI fusion imaging can be reduced by CEUS/
US fusion imaging, namely, real-time CEUS combined with
pretreatment three-dimensional US to obtain volume data,
because the breath-hold time is almost the same. The useful-
ness of CEUS/US fusion imaging for evaluation of the thera-
peutic efficacy of RFA has been reported previously [15];
however, the US volume data in that study were obtained by
manual sweep three-dimensional US. For a sonographer who
is not familiar with that modality, it may be difficult to main-
tain a constant speed of scanning without the transducer slip-
ping upon hitting a rib in manual-sweep three-dimensional
US, which may result in deformed volume data and, conse-
quently, inaccurate evaluation of the therapeutic efficacy of
RFA. In contrast, accurate US volume data can be obtained
with three-dimensional US in the auto sweep (VR AutoSweep;
GE Healthcare, Ltd. Chicago, IL) because the sonographer can
scan the tumor and surrounding liver parenchyma at a con-
stant scanning speed without needing to consider the pres-
ence of a rib, which allows more accurate evaluation of the
therapeutic efficacy of RFA. However, as of now, there are no
reports on evaluation of the therapeutic efficacy of RFA by
CEUS/US fusion imaging (with the volume data obtained by
AutoSweep three-dimensional US) for HCCs detected on con-
ventional US.
In this study, we compared the usefulness of intraproce-
dural CEUS/US fusion imaging (using the US volume data
obtained by AutoSweep three-dimensional US) for guiding
RFA and evaluating its therapeutic efficacy with that of CECT
or CEMRI performed 1month after RFA.
Materials and methods
Subjects
This uncontrolled clinical trial was conducted with the
approval of our institutional review board and in compliance
with the principles of the Declaration of Helsinki after obtain-
ing informed consent from each of the participating patients.
Between June 2017 and June 2018, we performed percutan-
eous RFA in 80 consecutive patients (with 93 HCCs) at our
institution. Forty-three of these 80 patients (with 50 HCCs)
were enrolled in the study.
The inclusion criteria were as follows: (1) age 20 years or
older; (2) a maximum of three HCC lesions, each measuring
less than 3 cm in diameter; (3) a platelet count of more than
5 104/mL; (4) patient able to breath-hold; (5) a well-defined
HCC margin on conventional US; (6) underlying hepatitis or
cirrhosis classified as Child-Pugh grade A or B; (7) patient
ineligible or unwilling to undergo surgery and (8) treatment
scheduled with RFA alone.
The exclusion criteria were as follows: (1) HCC unable to be
visualized adequately by CEUS because of bowel gas or the
lesion being located more than 12 cm from the skin surface; (2)
CECT or CEMRI unable to be performed because of a contra-
indication to use of intravenous iodinated contrast agents (aller-
gic reaction or impaired renal function); (3) HCC located behind
the portal vein, rendering accurate puncture of the lesion dur-
ing RFA difficult; (4) presence of portal vein and or hepatic vein
tumor thrombi and (5) presence of extrahepatic metastases.
The remaining 37 patients (with 43 HCCs) were excluded
for the following reasons: the lesion(s) showed isoechoic or
unclear margins on conventional US and were treated by
RFA under CEUS/CECT or CEMRI fusion imaging guidance (17
patients, 20 HCCs); conventional RFA was used to treat the
lesions (20 patients, 23 HCCs); there was a contraindication
to use of an intravenous iodinated contrast agent (seven
patients, eight HCCs), the lesion(s) could not be evaluated in
detail by CEUS (eight patients, nine HCCs); and difficulty
breath-holding sufficiently during fusion imaging (five
patients, six HCCs). Finally, 43 patients with 50 well-defined
hyperechoic or hypoechoic HCC lesions on conventional US
who underwent RFA under CEUS/US fusion imaging guid-
ance were enrolled in the study.
Diagnosis of typical HCC
Diagnosis of typical HCC was established based on the radio-
logical features of the lesion [16]. When a tumor did not
show a typical enhancement pattern on CECT/CEMRI, the
diagnosis was established by biopsy.
US imaging
Conventional US
First, we assessed the HCC lesions using the LOGIQ E9 ultra-
sound system (GE Healthcare, Ltd. Chicago, IL), with native tis-
sue harmonic gray-scale imaging using a convex probe with a
frequency of 1–6MHz and a micro-convex probe with a fre-
quency of 2–5MHz (hereafter referred to as conventional US).
CEUS procedure
As previously reported [17,18], a perflubutane microbubble
contrast agent (Sonazoid; Daiichi Sankyo, Tokyo, Japan) was
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injected into an antecubital vein at a dose of 0.2ml via a 24-
gauge cannula and followed by injection of 2ml of 5% glu-
cose. CEUS images were acquired during three contrast
phases, including the arterial phase (10–50 s after the start of
injection), portal phase (80–120 s after the start of injection)
and post-vascular phase (10min after the start of injection).
Using CEUS based on native tissue harmonic imaging at a
low mechanical index (0.28) and a high frame rate (28–30
frames per second), the tumor vessels and staining could be
evaluated in detail and in real time [17,18].
Fusion imaging
The fusion imaging system used in the study consisted of a
position sensing unit mounted on an US unit, a magnetic
transmitter, and a position sensor internally equipped with a
US probe. The transmitter was placed on a stand so that the
area being scanned was within the range of the transmitter.
Using the position sensor attached to the transducer, the
fusion feature allowed us to import pre-obtained volumetric
Digital Imaging and Communication in Medicine (DICOM)
data and to register the US images with the pre-obtained
volumetric digital images.
In this study, we used a convex volume probe with a fre-
quency of 2–5MHz to import pre-obtained three-dimensional
US volume data obtained by AutoSweep and then fused the
conventional US image and three-dimensional US volume
data (Figures 1 and 2(a)). Scanning to obtain the three-
dimensional US volume data was performed immediately
prior to RFA under breath-holding with the patient kept
immobilized.
To achieve adequate registration by minimizing the regis-
tration error while fuzing conventional US or CEUS and the
three-dimensional US images, we implemented the following
modifications: (1) immobilization of the patient during the
RFA procedure; (2) minimization of the distance between the
magnetic transmitter and the position sensor and (3) fusion
of the conventional US or CEUS and three-dimensional US
images of the bifurcation of the portal vein obtained during
a single breath-hold. After suitable registration of the con-
ventional US or CEUS and three-dimensional US volume
data, the results of conventional US or CEUS scanning were
Figure 1. Comparison of three-dimensional ultrasound (3DUS) volume data images obtained by manual sweep scanning and AutoSweep scanning for an HCC
lesion (maximum diameter, 28mm) in segment VIII of the liver. (a) 3DUS volume data image obtained by manual sweep scanning. Blue lines indicate the locus of
the manual sweep scanning. Arrow indicates the first frame of the manual sweep scanning. The distances between the blue lines are not equal, which indicates a
non-constant scanning speed. (b) 3DUS volume data image obtained by manual sweep scanning. (c) 3DUS obtained by manual sweep allows viewing of the vol-
ume of interest in three orthogonal planes (this image shows plane B), which can be translated from right to left. The shape of the arc is not symmetrical due to
the non-constant scanning speed (arrow). (d) US volume data image obtained by AutoSweep scanning. Comparison with the image in Figure 1(b) obtained by
manual sweep shows that the images look almost the same. (e) 3DUS image obtained by AutoSweep allows viewing of the volume of interest in three orthogonal
planes (this image shows plane B), which can be translated from right to left. Comparison with the image shown in Figure 1(c) obtained by manual sweep shows
that the shape of the arc is symmetrical and the scanning range is slightly wider than that in the image shown in Figure 1(c) (arrow). Arrowhead indicates the mar-
gin of the HCC.
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viewed at the same time as the three-dimensional US vol-
ume data. Furthermore, we used GPS marks (Figure 2(b,c)) to
confirm the location of the HCC [17–22] and to identify the
margin of the treated HCC for evaluation of the efficacy of
RFA immediately after the procedure. After registration of
the CEUS and three-dimensional US images obtained during
a single breath-hold, we set the GPS marks at the largest cut
surface of the treated lesion, which was visualized as an HCC
Figure 2. A 70-year-old woman with an HCC lesion (maximum lesion diameter, 13mm) in segment VI of the liver. (a) Transcostal fusion imaging, combining real-
time conventional US imaging (left side) and AutoSweep three-dimensional ultrasound (3DUS) imaging to obtain volume data (right side), was performed prior to
the RFA and the image(s) is presented on a single screen. The fusion image shows a hypoechoic lesion (arrowhead) in segment VI of the liver. (b) Transcostal fusion
imaging, combining arterial-phase CEUS imaging (left side) and AutoSweep 3DUS to obtain volume data (right side), was performed immediately after the RFA pro-
cedure, and the image(s) is presented on a single screen; the lesion was evaluated by fusion imaging with GPS marks. The green cross numbers 1–4 indicate the
margin of the ablation area. The ablation margin was evaluated as inadequate because of the insufficient ablation margin (arrow), and additional ablation was per-
formed under CEUS/US fusion imaging. (c) Immediately after the additional ablation, transcostal fusion imaging, combining arterial-phase CEUS imaging (left side)
and Auto Sweep 3DUS to acquire volume data (right side), was performed and the image(s) is presented on a single screen; this lesion was evaluated using fusion
imaging with GPS marks. The green cross numbers 1–4 indicate the margin of the ablated HCC area. The ablation was evaluated as adequate, because no
enhanced areas were visible within the entire tumor during the arterial phase and an ablative margin (arrowheads) was present around the entire tumor area dur-
ing the arterial phase. Hepatobiliary phase EOB-MRI image obtained (d) before and (e) 1 month after the RFA. This lesion was judged as having been adequately
ablated, because a low-signal area (arrowheads) was observed during the hepatobiliary phase in the low-signal area covering the area (arrow) seen in (d). Local
tumor progression has not been identified during the 16 months that have elapsed since the RFA.
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with a well-defined margin on three-dimensional US images.
These marks simultaneously appeared as small green cross
marks on both the three-dimensional US and CEUS images,
becoming large box marks as the transducer moved.
Therefore, while scanning with the GPS marks in place, the
lesion could be detected by CEUS at almost the same pos-
ition as where the GPS marks were observed as green
cross marks.
Performing RFA under the guidance of US/US
fusion imaging
To use fusion imaging during RFA, the three-dimensional US
liver volume data were obtained before RFA under breath-
hold (Figure 1(d,e)). The first puncture of the RFA needle was
performed under the guidance of real-time conventional US
and three-dimensional US fusion imaging using the LOGIQ
E9 ultrasound system and a convex probe with a frequency
of 1–6MHz or a micro-convex probe with a frequency of
2–5MHz (Figure 2(a)). After an RFA procedure, the ablated
HCC lesion becomes hyperechoic, which makes it difficult to
identify the margin of the target lesion. The second (and
third) puncture of the RFA needle was also performed under
real-time conventional US and three-dimensional US fusion
imaging guidance to ensure accurate puncture of the target
lesion. After the initial RFA procedure, as mentioned above,
we evaluated the therapeutic efficacy of RFA by CEUS/US
fusion imaging because this modality allowed the residual
HCC and/or insufficiently ablated areas to be detected. We
then performed further ablation if necessary under the guid-
ance of CEUS/US fusion imaging.
One hepatology physician (KN) with more than 10 years of
experience in treating HCC by RFA performed all the proce-
dures. RFA was performed under local anesthesia in all cases.
The electrode was inserted at different sites, and overlapping
ablations were performed until the entire lesion was ablated,
as determined by CEUS/US fusion imaging.
Intraprocedural assessment of RFA
Evaluation of therapeutic efficacy using CEUS/US
fusion imaging
Immediately (about 5–10min) after ablation, we confirmed
the location of the ablated HCC using CEUS/US fusion imag-
ing with GPS marks, thereby differentiating the ablated HCC
from the ablated adjacent liver parenchyma and allowing
measurement of the width of the thinnest ablation margin
(Figure 2(b,c)). More specifically, we fused the images of the
largest cut surface of each lesion obtained by CEUS and the
three-dimensional US volume data obtained during a single
breath-hold. When the GPS marks were set at the margins of
the largest cut surface of the target tumor on the three-
dimensional US volume data, the extent of the tumor could
be visualized by the locations of the green cross marks on
CEUS. When the area of observation moved from the largest
cut surface of the tumor to the marginal area or outside of
the tumor, the GPS marks changed from green cross marks
to box marks. This allowed us to identify the margin of the
tumor. Using this procedure, we were able to determine
whether the ablation, i.e., the burn, covered the entire tumor
area. The CEUS findings were evaluated by two hepatology
physicians (KS and KN) to determine the effects of RFA.
The degree of ablation was classified as follows: a 5mm
or larger ablation margin present around the entire tumor
(grade A); an ablation margin around the entire tumor but
less than 5mm in diameter in some places (grade B); an
incomplete ablation margin around the tumor although no
residual tumor apparent (grade C); tumor not completely
ablated (grade D) [23]. A grade A evaluation indicated com-
plete ablation whereas grades B–D represented inadequate
ablation. However, in the case of HCCs located within 5mm
of relatively large vessels such as the portal vein or of the
liver surface, it might not be possible to obtain an ablation
margin of 5mm diameter; in these cases, grade B was con-
sidered to represent adequate ablation.
Figure 2. Continued
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Assessment of technical success and further ablation
If the ablation was evaluated as adequate, we deemed the
treatment to be complete. However, if the ablation was eval-
uated as inadequate, we performed additional ablation under
CEUS/US fusion imaging guidance (Figure 2(b)). We consid-
ered the treatment as complete if the ablation was evaluated
as adequate on CEUS/US fusion imaging (Figure 2(c)); if not,
no further ablation was considered possible.
Post-treatment assessment
Evaluation of therapeutic efficacy of RFA by CECT/CEMRI
The final treatment outcome was evaluated by CECT (n¼ 31)
and/or CEMRI (n¼ 19) performed 1month after RFA. To
determine the effects of RFA, the CECT/CEMRI findings
obtained before and after RFA were evaluated by two hepa-
tology physicians (KO and HN), neither of whom was
involved in the RFA procedure and both of whom were
blinded to all clinical information and radiological findings
(Figure 2(d,e)).
Follow-up protocol
All the HCCs that were treated by RFA were followed up by
either CECT or CEMRI at 3-monthly intervals. The follow-up
period ended in September 2019.
Local tumor progression after RFA
In cases with hypervascular HCC, local recurrence was diag-
nosed if any enhancement was seen in the margin of the
ablated areas in the arterial phase and washout during the
subsequent phases on the CECT or CEMRI images. In cases
with non-hypervascular HCC, local recurrence was diagnosed
when a hypointense lesion was detected adjacent to the
ablation zone on images acquired by CEMRI in the hepato-
biliary phase. All images were evaluated by two experienced
radiologists (HF and MC) working independently and blinded
to all clinical information.
Statistical analysis
Using the findings of CECT/CEMRI performed 1 month after
RFA as the reference standard, a statistical analysis was per-
formed to calculate the concordance rate for the results of
evaluation of the efficacy of RFA between the CECT/CEMRI
and CEUS/US fusion imaging. Agreement was graded accord-
ing to the kappa values (shown within parentheses) as fol-
lows: poor (0.20), fair (0.21–0.40), moderate (0.41–0.60),
good (0.61–0.80) or very good (0.81–1.0) [24]. The statistical
analyses were performed using statistical software (SPSS ver-
sion 22; IBM Corp., Armonk, NY).
Results
Patient information
The study included 43 patients (with 50 HCCs). Twenty-seven
patients had newly developed recurrent HCC and 16 had
newly diagnosed HCC. The characteristics of the patients at
baseline are summarized in Table 1.
Evaluation of therapeutic efficacy by CEUS/US fusion
imaging immediately after initial RFA
The registration success rate of CEUS/US fusion imaging was
100% (50/50). According to the first evaluation by intraproce-
dural CEUS/US fusion imaging performed during RFA, 33
HCCs were deemed to have been adequately ablated. The
remaining 17 HCCs were evaluated as not having been
adequately ablated. The mean number of insertions of the
RFA needle for the initial RFA was 2.6 (range 1–6) per tumor
(Table 2).
Evaluation of therapeutic efficacy by CEUS/US fusion
imaging performed immediately after additional RFA
Seventeen of the 50 HCCs that had been initially evaluated
as inadequately ablated underwent further ablation. After
additional ablation, 16 of the 17 HCCs were evaluated as
adequately ablated by CEUS/US fusion imaging. The remain-
ing HCC (maximum diameter, 27mm) was evaluated as inad-
equately ablated at both the initial evaluation and the
second evaluation after additional RFA. When this patient
was selected as a candidate for RFA, RFA appeared to be the
most suitable treatment. However, while waiting for the pro-
cedure to be performed, the lesion had grown rapidly and a
portion of it came to be located behind the portal vein. This
Table 1. Baseline characteristics of the patients with HCC.a,b
Characteristics HCC (n¼ 50)
Number of patients 43
Single lesion/two lesions/three lesions 37/5/1
Age (mean, range; years) 68, 44–88
Sex (male/female) 28/15
Etiology of HCC
Hepatitis B/hepatitis C/others 11/26/6
Child-Pugh classification
Class A/B 40/3
Mean diameter of the lesions
(range) in mm　　　
15.3 (8–29)
Number of lesions measuring
1–10/11–20/21–30mm in diameter
9/36/5
Mean follow-up period (range)
in months
21.4 (15–27)
Number of lesions locating
less than 5mm from vessels/bile
duct/liver surface
14/4/5
aOthers: alcohol, primary biliary cholangitis, idiopathic.
bVessels: the relatively large vessels such as the portal vein or hepatic vein.
Table 2. Mean number of insertions for the initial RFA and additional RFA.
Initial RFAa Additional RFAb Total
Number of nodules 50 17 50
Mean number of
punctures (range)c
2.6 (1–6) 1.6 (1–4) 3.2 (1–6)
RFA: radiofrequency ablation.
aFirst treatment session.
bAdditional ablation performed immediately after the ablative margin was
evaluated as being inadequate by intra-procedural CEUS-US fusion imaging
performed at the first treatment session.
cMean number of insertions of the RFA needle.
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portion could not be ablated adequately. No third ablation
was performed because it would have been impossible to
maintain an adequate puncture line for RFA. Therefore, this
lesion was diagnosed as a residual viable HCC (grade D), and
transcatheter arterial chemoembolization was performed
1.5months after this RFA procedure. The mean number of
insertions of the RFA needle for the additional RFA was 1.6
(range 1–4) per tumor (Table 2). All RFA procedures were
completed after the initial or second evaluation by CEUS/US
fusion imaging (Figure 3).
Complications
All the RFA treatments were performed in a single session
without serious adverse events or immediate or late proced-
ure-related complications.
Evaluation of therapeutic efficacy of RFA by intraproce-
dural CEUS/US fusion imaging performed during RFA com-
pared with that of CECT/CEMRI performed 1month after RFA
We classified the degree of ablation when the therapeutic
efficacy of RFA was evaluated by CEUS/US fusion imaging
performed during the RFA procedure and CECT (n¼ 31) and
by CEMRI (n¼ 19) performed 1month after RFA (Table 3).
According to the findings on CEUS/US fusion imaging per-
formed during the RFA procedure, the degree of ablation of
the HCCs was as follows: grade A, 24 (48%); grade B, 25
(50%); grade C, 0 HCCand grade D, 1 (2%) HCC. Twenty-three
of the 25 HCCs that were evaluated as showing grade B
ablation were located within 5mm of relatively large vessels,
such as the portal or hepatic vein or from the liver surface,
and the remaining two were located behind the puncture
line. Therefore, an ablation margin of >5mm could not be
obtained in these lesions.
One case evaluated as showing grade D ablation by
CEUS/US fusion imaging was also diagnosed as having
residual HCC by CECT/CEMRI performed 1month after RFA.
In contrast, the remaining 49 HCCs were evaluated as show-
ing no residual tumor by CECT/CEMRI performed 1month
after RFA. The concordance rate between the results of
evaluation of efficacy of RFA by CECT/CEMRI performed 1
month after RFA was used as the reference standard and
CEUS/US fusion imaging performed during the RFA proced-
ure was evaluated. The concordance rate for the HCCs eval-
uated as showing adequate ablation at the initial evaluation
(n¼ 33) and the HCCs that were adequately ablated only
after a second RFA procedure in the same session (n¼ 17)
Figure 3. Flow chart of evaluation of therapeutic efficacy of RFA by CEUS/US fusion imaging performed during the RFA procedure.
Table 3. Comparison of evaluation by CEUS-US fusion imaging and CECT/EOB-MRI for assessment of the tumor response after radio-
frequency ablation in cases of hepatocellular carcinoma.
CT/MRI
US/US fusion Grade Aa Grade Bb Grade Cc Grade Dd Tumor (n¼ 50)
Grade A 21 3 0 0 24
Grade B 3 22 0 0 25
Grade C 0 0 0 0 0
Grade D 0 0 0 1 1
Total 24 25 0 1 50
aGrade A (curative): a 5mm or greater ablative margin around the entire tumor.
bGrade B (relatively curative): an ablative margin around the tumor, but less than 5mm in diameter in some places.
cGrade C (relatively non-curative): only an incomplete ablative margin around the tumor, although no residual tumor was apparent.
dGrade D (non-curative): the tumor was not completely ablated.
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was 88% (29/33 in the former category and 15/17 in the lat-
ter category; i.e., identical). The overall concordance rate was
also 88% (44/50); the kappa value for agreement between
the findings of the two imaging modalities was 0.792 (95%
confidence interval 0.625–0.960).
Local tumor progression
The mean follow-up period after RFA was 21.4 (range 15–27)
months. During this time, the only HCC that was evaluated
as showing grade B ablation by both CEUS/US fusion imag-
ing performed during RFA and CEMRI performed 1 month
after RFA showed local tumor progression on follow-up
CEMRI at 10months after RFA. This ablated lesion was
located adjacent to a large portal vein; therefore, the abla-
tion margin on this side was less than 5mm. In contrast, the
ablation margins on the other sides were more than 5mm.
Local tumor progression in this case arose from areas of the
tumor adjacent to the portal vein.
Discussion
In this study, we used CEUS/US fusion imaging (by combin-
ing CEUS with Sonazoid and three-dimensional US volume
data acquisition by AutoSweep) to evaluate the therapeutic
efficacy of RFA. Ninety-eight percent (49/50) of all HCCs were
found to have an adequate ablation margin after one or two
RFA procedures. Comparison of the results of evaluation of
efficacy of RFA between CECT/CEMRI performed 1month
after RFA as the reference standard and CEUS/US fusion
imaging performed during the RFA procedure revealed a
concordance rate of 88% (44/50). Therefore, CEUS/US fusion
imaging during RFA may be a useful method for guiding
RFA as well as for evaluating its therapeutic efficacy.
Twenty-three of the 25 HCCs that were evaluated as
showing grade B ablation were located within 5mm of rela-
tively large vessels, such as the portal or hepatic vein or of
the liver surface, and a portion of each of the remaining two
HCCs was located behind the puncture line. Therefore, an
adequate ablation margin of more than 5mm (grade A)
around the entire tumor could not be achieved in 50% (25/
50) of the HCCs. However, local recurrence occurred during
follow-up (mean 21.4months; range 15–27months) in only
one of the cases that showed a grade B ablation margin.
This lesion was located adjacent to a large portal vein; there-
fore, the ablation margin on this side was less than 5mm.
The ‘cooling effect’ of the adjacent large portal vein could
have been the reason for local tumor progression in that
case. We often encounter cases in which an ablation margin
of more than 5mm around the entire tumor (grade A) can-
not be achieved because of the location of the HCC.
Therefore, we believe that the findings in this case can be
considered clinically representative.
CEUS/US fusion imaging with volume data obtained by
AutoSweep three-dimensional US has several advantages.
First, the amount of registration error is lower
with AutoSweep three-dimensional US than with manual
sweep three-dimensional US. When manual sweep
three-dimensional US is used, slight deformation is likely to
be seen in about 90-degrees rotated plane images from the
actual scanned areas. In contrast, no image deformation is
seen in AutoSweep three-dimensional US imaging performed
to obtain volume data, regardless of the skill of the operator.
Consequently, volume data obtained by AutoSweep three-
dimensional US are better for guiding RFA and evaluating its
therapeutic efficacy. Second, when using this technique, the
US volume data as reference are obtained just before the
RFA is performed. In contrast, CT or MRI as reference for
CEUS/CT or CEUS/MRI fusion imaging is usually performed
several days before RFA, when the patient’s respiratory status
and posture may be slightly different from those during the
actual RFA procedure. Moreover, accurate registration
between CEUS and CT/MRI is more difficult in patients in
whom there has been a rapid increase in ascites and/or rapid
growth of the target lesion, deformation of the gallbladder,
or disturbance caused by movement of abdominal gas. In
contrast, these factors have little impact on CEUS/US fusion
imaging. Furthermore, CEUS/US fusion imaging does not
involve radiation exposure and can be performed in patients
in whom CECT/CEMRI is contraindicated because of contrast
allergy or impaired renal function. CEUS/US fusion imaging
can also be performed in more patients within a given time
period than is possible with CEUS/CECT or CEUS/CEMRI
fusion imaging. Third, when the ablation is evaluated as
inadequate during the RFA procedure, additional ablation
can be undertaken immediately in the same RFA session.
These apparent advantages, especially the lack of need for
an additional RFA procedure, reduce the physical and mental
burden on patients, the length of hospital stay and the treat-
ment-related medical expenses.
In contrast, as with CEUS/CECT or CEMRI fusion imaging,
CEUS/US fusion imaging with the volume data obtained by
AutoSweep three-dimensional US has some disadvantages.
First, breath-hold is necessary for concordance of the images
obtained by the two imaging modalities. Registration error
occurs, with resulting discordance of the images obtained by
the two modalities if the patient cannot hold his/her breath
sufficiently. Moreover, registration error is inevitable in any
fusion imaging because of the changes in liver morphology
caused by respiration and/or slight movements of the
patient due to pain during RFA, and adjustments to repair
the registration error between the two modalities are needed
several times during RFA. In the present study, the discord-
ance rate between CEUS and CECT/CEMRI was found to be
12% (6/50), which may have been due to registration errors
caused by the various factors mentioned above. For patients
who cannot hold their breath sufficiently, it would be useful
if a motion tracking system could be developed in the near
future to compensate for the movements of the tumor with
respiration so as to maintain concordance between CEUS
and other US images [25]. Second, for US technicians who
are not familiar with fusion imaging, it takes some time
(2–3min) to achieve adequate registration between these
modalities. Auto-registration between the two modalities
would be useful to resolve this problem [26].
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The present study also has several limitations. First, the
volume data were obtained by AutoSweep three-dimensional
US. A three-dimensional US probe is slightly thick so is not
suitable for guiding accurate puncture, for which a two-
dimensional convex probe was used in this study. When a
probe of a different shape is placed on the patient’s skin, the
scanning probe angle becomes slightly different, which could
induce registration error between probes of different shapes.
In the future, this problem may be resolved if it becomes
possible to use phased array transducers that provide three-
dimensional information automatically by electronic scanning
[27]. Second, while the registration success rate was 100% in
this study, because the inclusion criterion for the target
HCCs was a well-defined margin on conventional US (78.5%
[73/93]), it was still impossible to evaluate the efficacy of RFA
in cases where the HCC was deep-seated in relation to the
skin surface [9.7% (9/93)] because of US attenuation and dis-
ruption caused by the tumor being located near bowel gas.
Third, HCCs showing an unclear margin on conventional US
[21.5% (20/93)] were excluded. However, if an unclear lesion
appeared as a defective area in the post-vascular phase of
CEUS imaging, this image is obtained as volume data and
used as a reference image, intraprocedural CEUS/CEUS fusion
imaging during RFA is possible for RFA guidance and evalu-
ation of the therapeutic efficacy of RFA. Fourth, the patient
sample size was relatively small. Further studies are needed
to assess whether this novel evaluation modality, which can
be applied immediately after RFA, can eliminate the need for
evaluation by CECT or CEMRI 1 month after RFA.
Conclusion
Use of fusion imaging that combines CEUS and AutoSweep
three-dimensional US to obtain volume data appears to be a
useful method for RFA guidance and evaluation of the thera-
peutic efficacy of RFA for HCCs with a well-defined margin
on conventional US.
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